^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Renal Cell Carcinoma
    Drug:Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Exelixis Press Release
    Title:

    Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma

    Published date:
    09/19/2018
    Excerpt:
    Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX (cabozantinib) tablets for the treatment of adults with advanced renal cell carcinoma (RCC) who have received prior vascular endothelial growth factor (VEGF) targeted therapy.
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    09/09/2016
    Excerpt:
    Cabometyx is indicated for the treatment of advanced renal cell carcinoma (RCC):…in treatment-naïve adults with intermediate or poor risk...in adults following prior vascular endothelial growth factor (VEGF) targeted therapy...
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    04/25/2016
    Excerpt:
    CABOMETYX is a kinase inhibitor indicated for the treatment of...patients with advanced renal cell carcinoma (RCC)...
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Published date:
    09/28/2021
    Excerpt:
    Medical treatment for advanced/metastatic papillary RCC...Cabozantinib is the preferred first-line agent for advanced papillary RCC without additional molecular testing [II, B].
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    ...the NCCN Panel has included cabozantinib as a category 2A preferred first-line treatment option for poor- and intermediate -risk groups.
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Lancet Oncol
    Title:

    Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

    Published date:
    06/05/2016
    Excerpt:
    Median overall survival was 21·4 months (95% CI 18·7–not estimable) with cabozantinib...Cabozantinib treatment also resulted in improved progression-free survival (HR 0·51 [95% CI 0·41–0·62]; p<0·0001) and objective response (17% [13–22] with cabozantinib vs 3% [2–6] with everolimus; p<0·0001)....Treatment with cabozantinib increased overall survival, delayed disease progression, and improved the objective response compared with everolimus.
    DOI:
    10.1016/S1470-2045(16)30107-3
    Trial ID:
    METEOR